Literature DB >> 21298813

Mass spectral analyses of the two major apolipoproteins of great ape high density lipoproteins.

Donald L Puppione1, Della Donna Lorenza2, Arthur D Laganowsky3, Sara Bassilian2, Puneet Souda2, Oliver A Ryder4, Julian P Whitelegge3.   

Abstract

The two major apolipoproteins associated with human and chimpanzee (Pan troglodytes) high density lipoproteins (HDL) are apoA-I and dimeric apoA-II. Although humans are closely related to great apes, apolipoprotein data do not exist for bonobos (Pan paniscus), western lowland gorillas (Gorilla gorilla gorilla) and the Sumatran orangutans (Pongo abelii). In the absence of any data, other great apes simply have been assumed to have dimeric apoA-II while other primates and most other mammals have been shown to have monomeric apoA-II. Using mass spectrometry, we have measured the molecular masses of apoA-I and apoA-II associated with the HDL of these great apes. Each was observed to have dimeric apoA-II. Being phylogenetically related, one would anticipate these apolipoproteins having a high percentage of invariant sequences when compared with human apolipoproteins. However, the orangutan, which diverged from the human lineage between 16 and 21 million years ago, had an apoA-II with the lowest monomeric mass, 8031.3 Da and the highest apoA-I value, 28,311.7 Da, currently reported for various mammals. Interestingly, the gorilla that diverged from the lineage leading to the humanchimpanzee branch after the orangutan had almost identical mass values to those reported for human apoA-I and apoA-II. But chimpanzee and the bonobo that diverged more recently had identical apoA-II mass values that were slightly larger than reported for the human apolipoprotein. The chimpanzee A-I mass values were very close to those of humans; however, the bonobo had values intermediate to the molecular masses of orangutan and the other great apes. With the already existing genomic data for chimpanzee and the recent entries for the orangutan and gorilla, we were able to demonstrate a close agreement between our mass spectral data and the calculated molecular weights determined from the predicted primary sequences of the respective apolipoproteins. Post-translational modification of these apolipoproteins, involving truncation and oxidation of methionine, are also reported.

Entities:  

Keywords:  Mass spectrometry; dimeric apoA-II. post-translational modifications; truncated apoA-II

Mesh:

Substances:

Year:  2009        PMID: 21298813      PMCID: PMC2776726          DOI: 10.1016/j.cbd.2009.09.001

Source DB:  PubMed          Journal:  Comp Biochem Physiol Part D Genomics Proteomics        ISSN: 1744-117X            Impact factor:   2.674


  29 in total

1.  Toward the bilayer proteome, electrospray ionization-mass spectrometry of large, intact transmembrane proteins.

Authors:  J P Whitelegge; J le Coutre; J C Lee; C K Engel; G G Privé; K F Faull; H R Kaback
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  Separation and characterization of human high-density apolipoproteins using a nonaqueous modifier in capillary electrophoresis-mass spectrometry.

Authors:  Leesa J Deterding; Jenny M Cutalo; Morteza Khaledi; Kenneth B Tomer
Journal:  Electrophoresis       Date:  2002-07       Impact factor: 3.535

3.  Mass spectral analysis of the apolipoproteins on mouse high density lipoproteins. Detection of post-translational modifications.

Authors:  Donald L Puppione; Lang M Yam; Sara Bassilian; Puneet Souda; Lawrence W Castellani; Verne N Schumaker; Julian P Whitelegge
Journal:  Biochim Biophys Acta       Date:  2006-06-18

4.  Isolation and characterization of several plasma apolipoproteins of common marmoset monkey.

Authors:  D Crook; K H Weisgraber; S C Rall; R W Mahley
Journal:  Arteriosclerosis       Date:  1990 Jul-Aug

5.  Some physical and chemical studies on two polypeptide components of high-density lipoproteins of human serum.

Authors:  V Shore; B Shore
Journal:  Biochemistry       Date:  1968-10       Impact factor: 3.162

6.  Preliminary evaluation of blood lipid profiles in captive western lowland gorillas (Gorilla gorilla gorilla).

Authors:  Eric J Baitchman; Paul P Calle; Tracy L Clippinger; Sharon L Deem; Stephanie B James; Bonnie L Raphael; Robert A Cook
Journal:  J Zoo Wildl Med       Date:  2006-06       Impact factor: 0.776

Review 7.  The plasma lecithins:cholesterol acyltransferase reaction.

Authors:  J A Glomset
Journal:  J Lipid Res       Date:  1968-03       Impact factor: 5.922

8.  Comparison of the structural and functional effects of monomeric and dimeric human apolipoprotein A-II in high density lipoprotein particles.

Authors:  S Lund-Katz; Y M Murley; E Yon; K L Gillotte; W S Davidson
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

9.  Sequence of horse (Equus caballus) apoA-II. Another example of a dimer forming apolipoprotein.

Authors:  Donald L Puppione; Wolfgang H Fischer; Minkyu Park; Julian P Whitelegge; Verne N Schumaker; Shoulamit Golfeiz; Melinda H MacDonald
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2004-07       Impact factor: 2.231

10.  Covalent structure of apolipoprotein A-II from Macaca mulatta serum high-density lipoproteins.

Authors:  C Edelstein; C Noyes; P Keim; R L Heinrikson; R E Fellows; A M Scanu
Journal:  Biochemistry       Date:  1976-03-23       Impact factor: 3.162

View more
  2 in total

1.  Homocysteinylated albumin promotes increased monocyte-endothelial cell adhesion and up-regulation of MCP1, Hsp60 and ADAM17.

Authors:  Rosanna Capasso; Irene Sambri; Amelia Cimmino; Sofia Salemme; Cinzia Lombardi; Filomena Acanfora; Ersilia Satta; Donald L Puppione; Alessandra F Perna; Diego Ingrosso
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

2.  Apolipoprotein a-I is a potential mediator of remote ischemic preconditioning.

Authors:  Pierre Hibert; Delphine Prunier-Mirebeau; Olivia Beseme; Maggy Chwastyniak; Sophie Tamareille; Delphine Lamon; Alain Furber; Florence Pinet; Fabrice Prunier
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.